Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16742
Country/Region: Ethiopia
Year: 2015
Main Partner: Ministry of National Defense - Ethiopia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $2,773,703 Additional Pipeline Funding: $50,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $236,028
Care: TB/HIV (HVTB) $182,383
Care: Pediatric Care and Support (PDCS) $20,000
Laboratory Infrastructure (HLAB) $50,000
Strategic Information (HVSI) $127,300
Health Systems Strengthening (OHSS) $95,000
Biomedical Prevention: Injection Safety (HMIN) $0
Testing: HIV Testing and Counseling (HVCT) $130,000
Sexual Prevention: Other Sexual Prevention (HVOP) $647,992
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $45,000
Treatment: Adult Treatment (HTXS) $1,200,000
Treatment: Pediatric Treatment (PDTX) $40,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 6,928
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 1,015
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 187
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2016 20
HRH_PRE Sum of Graduates disaggregates 2016 20
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 5,039
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 5,917
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 31,829
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 17,215
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 60,000
HTS_TST Sum of Aggregated Age/Sex <15 2016 10,956
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 49,044
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 60,000
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 4
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 31
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 75
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 72
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 47
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 25
PMTCT_ARV Sum of New and Current disaggregates 2016 72
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 54
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 14
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 68
PMTCT_EID Sum of Infant Age disaggregates 2016 68
PMTCT_STAT By: Known positives at entry 2016 53
PMTCT_STAT By: Number of new positives identified 2016 22
PMTCT_STAT Number of new ANC and L&D clients 2016 2,726
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 2,590
PMTCT_STAT Sum of Positives Status disaggregates 2016 75
PP_PREV Age/sex: 15-19 Female 2016 10,640
PP_PREV Age/sex: 15-19 Male 2016 2,160
PP_PREV Age/sex: 20-24 Female 2016 11,306
PP_PREV Age/sex: 20-24 Male 2016 2,295
PP_PREV Age/sex: 25-49 Female 2016 44,721
PP_PREV Age/sex: 25-49 Male 2016 4,976
PP_PREV Age/sex: 50+ Female 2016 333
PP_PREV Age/sex: 50+ Male 2016 69
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 76,500
PP_PREV Sum of Age/Sex disaggregates 2016 76,500
PP_PREV Total number of people in the target population 2016 191,250
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 6,928
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 6,789
TX_CURR Age/Sex: <1 Female 2016 13
TX_CURR Age/Sex: <1 Male 2016 16
TX_CURR Age/Sex: 1-4 Female 2016 48
TX_CURR Age/Sex: 1-4 Male 2016 54
TX_CURR Age/Sex: 5-14 Female 2016 94
TX_CURR Age/Sex: 5-14 Male 2016 92
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 6,759
TX_CURR Sum of age/sex disaggregates 2016 6,759
TX_NEW By Age/Sex: <1 Female 2016 3
TX_NEW By Age/Sex: <1 Male 2016 4
TX_NEW By Age/Sex: 1-4 Female 2016 9
TX_NEW By Age/Sex: 1-4 Male 2016 12
TX_NEW By Age/Sex: 10-14 Female 2016 6
TX_NEW By Age/Sex: 10-14 Male 2016 6
TX_NEW By Age/Sex: 15-19 Female 2016 13
TX_NEW By Age/Sex: 15-19 Male 2016 5
TX_NEW By Age/Sex: 20-24 Female 2016 92
TX_NEW By Age/Sex: 20-24 Male 2016 18
TX_NEW By Age/Sex: 25-49 Female 2016 175
TX_NEW By Age/Sex: 25-49 Male 2016 552
TX_NEW By Age/Sex: 5-9 Female 2016 11
TX_NEW By Age/Sex: 5-9 Male 2016 13
TX_NEW By Age/Sex: 50+ Female 2016 12
TX_NEW By Age/Sex: 50+ Male 2016 31
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 962
TX_NEW Sum of Age/Sex disaggregates 2016 962
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 822
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 968
Cross Cutting Budget Categories and Known Amounts Total: $315,251
Gender: Gender Based Violence (GBV) $13,706
Post GBV Care
Implementation
Food and Nutrition: Policy, Tools, and Service Delivery $27,413
Human Resources for Health $274,132